Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center
Issued Date
2022-06-01
Resource Type
ISSN
1355008X
eISSN
15590100
Scopus ID
2-s2.0-85128803374
Pubmed ID
35476179
Journal Title
Endocrine
Volume
77
Issue
1
Start Page
134
End Page
142
Rights Holder(s)
SCOPUS
Bibliographic Citation
Endocrine Vol.77 No.1 (2022) , 134-142
Suggested Citation
Kanokwongnuwat W., Larbcharoensub N., Sriphrapradang C., Suppasilp C., Thamnirat K., Sakulpisuti C., Kositwattanarerk A., Utamakul C., Sritara C., Chamroonrat W. Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center. Endocrine Vol.77 No.1 (2022) , 134-142. 142. doi:10.1007/s12020-022-03060-5 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83725
Title
Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center
Author's Affiliation
Other Contributor(s)
Abstract
Purpose: This article aims to review and assess the post-operative management and treatment outcomes of papillary thyroid microcarcinoma (PTMC) in risk-stratified patients. Methods: We retrospectively analyzed the data of PTMC patients who underwent thyroid surgery with or without radioactive iodine treatment (RAI) in a single center between January 2011 and December 2017. Demographic and clinicopathologic data were collected. Risk stratification according to the 2015 American Thyroid Association guideline was applied. Results: Three hundred forty PTMC patients were included. Post-operative RAI was performed in 216/340 (63.53%) patients. In the non-RAI scenario, there were 122 low-risk and two intermediate-risk patients. In total, 261 (76.77%), 57 (16.76%), and 22 (6.47%) patients were classified as low, intermediate, and high risk, respectively. With a median follow-up time of 36 months (interquartile range: 23, 52), we found unfavorable outcomes (evidenced by imaging or out-of-range serum tumor marker levels: high thyroglobulin [Tg] or rising Tg antibody [TgAb] levels) in 8/340 (2.35%) patients, all of which received RAI. PTMC patients with unfavorable outcomes were stratified as low risk (4/261 [1.53%]), intermediate risk (1/57 [1.75%]), or high risk (3/22 [13.64%]). One death occurred in a patient with initial distant metastasis in the high-risk group. Initial high-risk stratification and initial stimulated Tg (of at least 10 ng/mL) were demonstrated as independent predictors for PTMC unfavorable outcomes (persistent or recurrent disease). Five patients with unfavorable outcomes (four with persistent disease and one with recurrent disease) had abnormal Tg or TgAb values despite unremarkable imaging findings. Moreover, 79/124 (63.71%) patients in the non-RAI scenario were only followed up with neck ultrasound. Conclusions: In general, at least 98% of low-risk and intermediate-risk PTMC patients showed favorable outcomes without persistent or recurrent disease, defined by either imaging or serum tumor markers. Nevertheless, aggressive disease could occur in few PTMC patients. Decisions on post-operative management and follow-up may be guided by initial high-risk stratification and initial stimulated Tg levels (≥10 ng/mL) as independent predictors for PTMC unfavorable outcomes. Monitoring using both imaging and serum tumor markers is crucial and should be implemented for patients with PTMC.